首页 Adaptive Biotechnologies Corp(usADPT)-基本信息

Adaptive Biotechnologies Corp(usADPT)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:39.8

最高价:41.895

成交量:301502.0

昨收价:40.3

最低价:39.36

最新价:41.825

行情图标
概要信息

英文名称:Adaptive Biotechnologies Corp


行业:医疗


简介:Adeptus Health Inc.于2014年3月7日在特拉华成立


电话:1-972-8996666


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Adaptive Biotechnologies公司认为适应性免疫系统是自然界最精细调整的诊断和治疗方法,可以用于治疗大多数疾病,但无法解码它使医学界无法充分利用其能力。Adaptive Biotechnologies的免疫医学平台(Immune Medicine Platform)应用公司的专有技术来读取患者免疫系统的各种遗传密码,并准确了解它如何检测和治疗患者的疾病。Adaptive Biotechnologies利用计算机基础设施进行高通量基因测序,使科学家能够精确分析T细胞受体(TCR)。这项新技术使科学家能够在一个人身上识别出1000万到1500万个独特的TCRs。Adaptive Biotechnologies公司在动态临床免疫组学数据库中捕获这些见解,该数据库以计算生物学和机器学习为基础,并利用它们开发和商业化公司为每个患者定制的临床产品和服务。Adaptive Biotechnologies有两种商业产品和服务以及一系列强大的临床产品和服务,公司正在设计这些产品和服务来诊断、监测和实现癌症、自身免疫疾病和传染病等疾病的治疗。自2009年成立以来,Adaptive Biotechnologies已识别超过200亿个免疫受体,与125家生物制药公司建立了合作伙伴关系和商业关系,并推出了两条产品线。公司的目标是了解适应性免疫系统,并将其转化为具有前所未有的规模,精度和速度的新产品。Adaptive Biotechnologies公司的免疫医学平台(Immune Medicine Platform)是其不断扩展的产品和服务套件的基础,平台和核心和免疫测序产品的基石是immunoSEQ,作为公司的基础研究和开发引擎,并从学术和生物制药客户获得收入。Adaptive Biotechnologies的第一个临床诊断产品——clonoSEQ,是FDA授权的首个检测和监测选择性血癌患者微小残留病的检测方法。利用与微软(微软投资该公司4500万美元)的合作,Adaptive Biotechnologies还开发了一种诊断产品immunoSEQ Dx,可以通过单次血液检测早期发现许多疾病。根据与罗氏旗下Genentech的合作协议开发的治疗产品候选产品利用公司的平台识别特定的免疫细胞,以发展成肿瘤学中的细胞疗法。公司相信这种方法有可能适用于各种癌症患者。Adaptive Biotechnologies公司估计其投资组合的潜在市场机会将超过480亿美元,包括研究产品,临床诊断和细胞疗法。 随着临床医生越来越意识到免疫系统在疾病诊断和治疗中的重要性以及公司的产品和服务管道不断扩大,相信这个市场会随着时间的推移而增长。Adaptive Biotechnologies(ADPT)融资百科:2011年6月9日,Adaptive TCR Corporation在B轮融资中获得了580万美金的投资。2014年4月7日,Adaptive Biotechnologies宣布完成C轮融资,使公司的总融资额达到2000万美元。2014年4月15日,Adaptive Biotechnologies宣布完成D轮融资,D轮由Viking Global Investors独家投资1亿美金。使公司的总融资额达到1.2亿美金。2015年1月7日,Adaptive Biotechnologies宣布完成E轮9400万美元融资。2015年5月6日,Adaptive Biotechnologies 宣布完成1.95亿美金的F轮融资,由Matrix Capital Management领投,跟投的包括新投资者Senator Investment Group, Tiger Management, Rock Springs Capital 以及原有投资者 Viking Global Investors, Casdin Capital 和 Alexandria Real Estate Equities。截止上市前,Adaptive Biotechnologies共计融资4.069亿美金。Adaptive Biotechnologies(ADPT)历史百科:2018年初,Adaptive与Microsoft合作开发了一种可以在一次检测中诊断多种疾病的血液检测。该合作是利用人工智能和机器学习技术来解码人体免疫系统对外来物质和毒素的反应。2019年1月,两家公司宣布,准备推出帮助25000名患有五种疾病的人排序免疫数据,这五种疾病包括1型糖尿病,乳糜泻,卵巢癌,胰腺癌和莱姆病。2019年1月,Adaptive与罗氏旗下基因泰克 达成协议,开发、生产和商业化新型抗原定向T细胞疗法,用于个体化治疗多种癌症。该协议金额高达20亿美元。该合作将把基因泰克的免疫疗法研究成果及药物,与Adaptive专有的T细胞抗原受体(TCR)发现和免疫分析平台TruTCR相结合,目的是加速研发对每位患者个体化癌症定制细胞疗法的转型新治疗范例。Adaptive Biotechnologies将使用其研究性TCR发现平台来确定患者体内最佳的T细胞抗原受体,以便能够最有效地针对每位患者的个体化抗原进行治疗。(以上两段来自新浪医药)

交易日期 交易人 职位 类型 交易份额 价格
2017-02-02 Prescott Group Capital Managemen Beneficial Owner of More than 10% Class Sell 102192 7.21
2017-01-02 Napolitano (Steven V) Director Buy 8834 --
2017-01-02 Mengert (Stephen Michael) Director Buy 8834 --
2017-01-02 Sterling Capital Partners Iii L Beneficial Owner of More than 10% Class Buy 8834 --
2017-01-02 Taylor (Ronald L) Director Buy 8834 --
2017-01-02 Vender Jeffery S Director Buy 8834 --
2017-01-02 Covert Richard Director and Beneficial Owner Buy 8834 --
2016-11-06 Williams (Frank Richard Jr) Chief Financial Officer Buy 117924 --
2016-11-06 Scott (Gregory W) Chief Executive Officer Buy 35377 --
2016-08-28 Williams (Frank Richard Jr) Chief Financial Officer Buy 22326 --
2016-06-07 Sterling Capital Partners Iii L Beneficial Owner of More than 10% Class Sell 1043281 60.53
2016-02-28 Hall (Thomas S) Chief Executive Officer Buy 86768 --
2016-02-24 Bowen Traci Officer Buy 4881 --
2016-02-24 Jordan (Andrew M) Officer Buy 4881 --
2016-02-24 Cherrington (Graham B) President Buy 23861 --
2016-02-24 Muzzarelli James Officer Buy 4881 --
2016-02-24 Fielding Timothy Chief Financial Officer Buy 4881 --
2016-01-03 Covert Richard Director and Beneficial Owner Buy 1371 --
2016-01-03 Vender Jeffery S Director Buy 1371 --
2016-01-03 Taylor (Ronald L) Director Buy 1371 --
2016-01-03 Sterling Capital Partners Iii L Beneficial Owner of More than 10% Class Buy 1371 --
2016-01-03 Napolitano (Steven V) Director Buy 1371 --
2016-01-03 Scott (Gregory W) Director Buy 1371 --
2016-01-03 Mengert (Stephen Michael) Director Buy 1371 --
2015-08-03 Sterling Capital Partners Iii L Beneficial Owner of More than 10% Class Sell 1264723 100.54
2015-06-28 Napolitano (Steven V) Director Buy 812 --
2015-06-28 Taylor (Ronald L) Director Buy 812 --
2015-06-28 Vender Jeffery S Director Buy 812 --
2015-06-28 Covert Richard Director and Beneficial Owner Buy 812 --
2015-06-28 Sterling Fund Management L L C Director Buy 812 --
第 页, 共 2 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Vanguard Investments Australia Ltd 64202 0.05% 64202 -- 2019-07-31
Pictet Asset Management (Europe) SA 276779 0.22% 276779 -- 2019-07-31
T. Rowe Price Associates, Inc. 324696 0.26% 324696 -- 2019-07-31
Fidelity Management & Research Company 357162 0.29% 357162 -- 2019-07-31
Baron Capital Management Inc 421139 0.34% 421139 -- 2019-07-31
BAMCO Inc 564204 0.46% 564204 -- 2019-07-31
BlackRock Advisors LLC 572163 0.46% 572163 -- 2019-07-31
Capital Research and Management Company 600000 0.49% 600000 -- 2019-07-31
Massachusetts Financial Services Company 614900 0.50% 614900 -- 2019-07-31
J.P. Morgan Investment Management, Inc. 260141 0.21% 260141 -- 2019-07-31
Vanguard Group Inc 199525 0.16% 199525 -- 2019-07-31
Loomis Sayles & Company LP 196287 0.16% 196287 -- 2019-07-31
Fidelity SelectCo, LLC 72200 0.06% 72200 -- 2019-07-31
AMG Funds LLC 74613 0.06% 74613 -- 2019-07-31
Wells Fargo Funds Management LLC 90371 0.07% 90371 -- 2019-07-31
Fidelity Management Trust Co 126900 0.10% 126900 -- 2019-07-31
Invesco Ltd (OFI / OppenheimerFunds) 140243 0.11% 140243 -- 2019-07-31
Columbia Mgmt Investment Advisers, LLC 153966 0.12% 153966 -- 2019-07-31
American Century Investment Management, Inc 177091 0.14% 177091 -- 2019-07-31
PGIM Investments LLC 191481 0.16% 191481 -- 2019-07-31
Invesco Advisers, Inc. 53039 0.04% 53039 -- 2019-07-31
Strategic Advisers LLC 58800 0.05% 58800 -- 2019-07-31
AGF Investments 108 -- 108 -- 2019-06-30
Tetrem Capital Management Ltd. 400 -- 400 -- 2019-06-30
Kredietrust Luxembourg S.A. 2333 -- 2333 -- 2019-06-30
Driehaus Capital Management LLC 17766 0.01% 17766 -- 2019-06-30
Morgan Stanley & Co Inc 1077542 5.10% 1044031 3115.49% 2016-09-30
BlackRock Fund Advisors 1077645 5.10% 174156 19.28% 2016-09-30
Franklin Advisers Inc 1093676 5.18% 229211 26.51% 2016-09-30
Bank Of New York CO Inc. 1106399 5.24% 605560 120.91% 2016-09-30
Tpg-axon Capital Management Lp 1530863 7.25% 62780 4.28% 2016-09-30
Deerfield Management Co 1600861 7.58% -- -- 2016-09-30
Sterling Capital Partners III, LLC 4804339 23.13% -4950741 -50.75% 2015-12-31
EverPoint Asset Management, LLC 560000 2.70% 560000 -- 2016-03-18
Boston Co Asset Management LLC 679989 3.22% 332338 95.60% 2016-09-30
Eagle Asset Management, Inc. 679615 3.22% 47438 7.50% 2016-09-30
Fidelity Institutional Asset Management 306700 1.45% 186600 155.37% 2016-09-30
State Street Corp 335920 1.59% -10320 -2.98% 2016-09-30
NorthPointe Capital LLC 339189 1.61% 339189 -- 2016-09-30
Southpoint Capital Advisors LP 362901 1.72% -53828 -12.92% 2016-09-30
Peregrine Capital Management Inc 375465 1.78% 375465 -- 2016-09-30
Goldman Sachs Asset Management LP 439925 2.08% -213370 -32.66% 2016-09-30
Kennedy Capital Management Inc 552660 2.62% 260158 88.94% 2016-09-30
Delaware Management Business Trust 763616 3.62% 563552 281.69% 2016-09-30
Daniel J. Hosler 9755080 3.00% 485802984 0.50% 1999-11-30
Richard Covert 1749483 3.00% 87124253 0.10% 1999-11-30
Daniel W. Rosenberg 9755080 3.00% 485802984 0.50% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Invesco Oppenheimer Discovery Fund 85707 0.07% 85707 -- 2019-06-30
MFS 202169 0.16% 202169 -- 2019-06-30
T. Rowe Price Small-Cap Stock Fund 206485 0.17% 206485 -- 2019-06-30
Pictet TR - Divers Alpha 266840 0.22% 266840 -- 2019-06-30
MFS New Discovery Fund 379446 0.31% 379446 -- 2019-06-30
Baron Growth Fund 421139 0.34% 421139 -- 2019-06-30
Baron Small-Cap Growth Strategy-UBS 421139 0.34% 421139 -- 2019-06-30
BlackRock Mid-Cap Growth Equity Port 522063 0.42% 522063 -- 2019-06-30
American Funds SMALLCAP World Fund 600000 0.49% 600000 -- 2019-06-30
Loomis Sayles Small Cap Growth Fund 196287 0.16% 196287 -- 2019-06-30
American Century Small Cap Growth Fund 172263 0.14% 172263 -- 2019-06-30
JPMorgan Small Cap Growth Fund 162863 0.13% 162863 -- 2019-06-30
Columbia Small Cap Growth Fund I 131369 0.11% 131369 -- 2019-06-30
Fidelity Growth Company Commingled Pool 122900 0.10% 122900 -- 2019-06-30
PGIM Jennison Health Sciences Fund 111262 0.09% 111262 -- 2019-06-30
T. Rowe Price Instl Small-Cap Stock Fund 108976 0.09% 108976 -- 2019-06-30
T. Rowe Price US SmCp Core Equity Tr 108976 0.09% 108976 -- 2019-06-30
Fidelity 106600 0.09% 106600 -- 2019-06-30
Baron Small Cap Fund 101149 0.08% 101149 -- 2019-06-30
PGIM Jennison Small Company Fund 79704 0.06% 79704 -- 2019-06-30
GWL Growth Equity (A) 100/100 18 -- 18 -- 2019-06-30
London Life Growth Equity (A) 90 -- 90 -- 2019-06-30
Global Voyager North American Equity 400 -- 400 -- 2019-06-30
Essential Port Sel US Equity 2333 -- 2333 -- 2019-06-30
Driehaus Small Cap Growth Fund 17766 0.01% 17766 -- 2019-06-30
Strategic Advisers 147811 0.70% -145270 -49.57% 2016-11-30
DFA US Small Cap Value II 61779 0.29% -- -- 2016-12-31
JNL/Mellon Capital Healthcare Sector B 12153 0.06% -- -- 2016-09-30
Columbia Small Cap Index Z 74930 0.35% 150 0.20% 2016-12-31
Vanguard Small Cap Growth Index Inv 81319 0.39% -80773 -49.83% 2016-12-31
Vanguard Explorer Inv 186190 0.88% -8460 -4.35% 2016-09-30
Franklin Small Cap Growth A 1000600 4.74% -- -- 2016-12-31
FIAM Small Cap Core Pool 141900 0.67% 101000 246.94% 2016-09-30
Guggenheim S&P SmallCap 600 448311 1.90% -- -- 2017-02-08
Gabelli Dividend & Income 65000 0.31% 65000 -- 2016-09-30
Vanguard Total Stock Mkt Idx 288080 1.36% -- -- 2016-12-31
JNL/Mellon Capital Small Cap Index B 44378 0.21% 5139 13.10% 2016-09-30
iShares S&P Small-Cap 600 Value 204174 0.93% 286 0.14% 2017-02-07
Gabelli Health & Wellness 95000 0.45% 44791 89.21% 2016-09-30
Principal SmallCap S&P 600 Idx SP 84179 0.40% 154 0.18% 2016-12-31
Rydex S&P SmallCap 600 Pure Value C 84200 0.40% 84200 -- 2016-12-31
Gabelli Asset AAA 15000 0.07% 15000 -- 2016-09-30
iShares Russell 2000 Growth 110457 0.50% -- -- 2017-02-07
Vanguard Small Cap Index 146638 0.69% -137868 -48.46% 2016-12-31
Vanguard Extended Market Idx Inv 176983 0.84% 7694 4.54% 2016-12-31
T. Rowe Price New Horizons Fund 776789 3.70% 379600 95.60% 2015-09-30
Goldman Sachs Growth Opportunities Fund 750171 3.60% 213111 39.70% 2015-10-31
T. Rowe Price Health Sciences Fund 615398 3.00% 376798 157.90% 2015-09-30
Goldman Sachs Small/Mid Cap Growth Fund 453145 2.20% 14410 3.30% 2015-09-30
Fidelity® Blue Chip Growth Fund 437500 2.10% 59000 15.60% 2015-09-30
Fidelity® Select Health Care Portfolio 400000 1.90% 25000 6.70% 2015-09-30
Franklin Small Cap Growth Fund 302700 1.50% -223300 -42.50% 2015-09-30
Vanguard Explorer Fund 185683 0.90% 152600 461.30% 2015-09-30
Fidelity® Series Blue Chip Growth Fund 149967 0.70% 18500 14.10% 2015-09-30
Fidelity Advisor® Health Care Fund 140000 0.70% 19990 16.70% 2015-09-30
Vanguard Small Cap Growth Index Fund 141137 0.70% -3204 -2.20% 2015-10-31

Robert M. Hershberg Founder of VentiRx Pharmaceuticals, Inc., Robert M. Hershberg is on the board of NanoString Technologies, Inc., Adaptive Biotechnologies Corp. and Silverback Therapeutics, Inc. In the past Dr. Hershberg was Chief Scientific Officer at Celgene Corp. and President, Chief Executive Officer & Director at VentiRx Pharmaceuticals, Inc. (a subsidiary of Celgene Corp.), Chief Medical Officer & Senior Vice President for Dendreon Corp., Vice President-Medical Genetics at Corixa Corp. and Assistant Professor at Harvard Medical School. Dr. Hershberg received a doctorate and an undergraduate degree from the University of California, Los Angeles and a doctorate from The Salk Institute for Biological Studies.
Kevin T. Conroy Kevin T. Conroy holds the position of Chairman, President & Chief Executive Officer of EXACT Sciences Corp. He is also on the board of 7 other companies. In the past he held the position of Partner at McDermott Will & Emery LLP, Director at Bioforward, Inc., Partner at Pattishall, McAuliffe, Newbury, Hilliard & Geraldson LLP, President & Chief Executive Officer of Third Wave Technologies, Inc. and Counsel-Intellectual Property at GE Healthcare Ltd. Mr. Conroy received an undergraduate degree from Michigan State University and a graduate degree from The University of Michigan Law School.
Peter M. Neupert Peter M. Neupert is on the board of Laboratory Corp. of America Holdings and 7 other companies. He previously held the position of Vice President-Health Solutions Group at Microsoft Corp., Operating Partner at Health Evolution Management Co. LLC, Chairman of drugstore.com LLC and Member of Institute of Medicine. He received an undergraduate degree from Colorado College and an MBA from Tuck School of Business at Dartmouth.
Eric L. Dobmeier Eric L. Dobmeier is on the board of Atara Biotherapeutics, Inc. and Adaptive Biotechnologies Corp. In the past he occupied the position of President & Chief Executive Officer of Silverback Therapeutics, Inc., Chief Operating Officer at Seattle Genetics, Inc. and Principal at Heller Ehrman LLP and Principal at Venture Law Group (a subsidiary of Heller Ehrman LLP). He received an undergraduate degree from Princeton University and a graduate degree from Berkeley Law University of California.
Lance Baldo Lance Baldo founded MedAptus, Inc. Presently, Dr. Baldo is Chief Medical Officer for Adaptive Biotechnologies Corp. He received a doctorate from the University of Connecticut and an undergraduate degree from The Johns Hopkins University.
Sean Nolan Currently, Sean Nolan holds the position of Chief Technical Officer for Adaptive Biotechnologies Corp. Mr. Nolan previously occupied the position of Chief Architect at WebRelevance, Inc. He received an undergraduate degree from Dartmouth College.
Michael J. Pellini Currently, Michael J. Pellini occupies the position of Managing Partner at Section 32 LLC. He is also Member-Technology Council at Boston College and on the board of 8 other companies. In the past he was Vice President-Life Sciences Group at Safeguard Scientifics, Inc., Chairman at Foundation Medicine, Inc., President & Chief Executive Officer at Genomics Collaborative, Inc., President & Chief Operating Officer for Clarient, Inc., Chief Operating Officer & Executive Vice President for PLUS Diagnostics, Inc. and Investment Committee Member at Ben Franklin Technology Partners. He received an undergraduate degree from Boston College, an MBA from Drexel University, a doctorate from Sidney Kimmel Medical College and an undergraduate degree from Thomas Jefferson University.
Andris A. Zoltners Andris A. Zoltners is the founder of ZS Associates, Inc. He is on the board of Adaptive Biotechnologies Corp.
Nancy L. Hill Nancy L. Hill founded Zaltana Strategies LLC. Currently, she is Senior Vice President-Operations at Adaptive Biotechnologies Corp. In her past career she occupied the position of Principal at Amgen, Inc. and Senior Director-Oncology Marketing at Immunex Corp. (a subsidiary of Amgen, Inc.), Principal at Lederle Laboratories, Principal at Bayer Healthcare LLC and Vice President-Marketing & Business Development at Spiration, Inc. Ms. Hill received an MBA from Northwestern University and an undergraduate degree from the University of Washington.
David Espina Goel Founder of Matrix Capital Management Co. LP and Matrix Capital Management Fund LP, David Espina Goel currently occupies the position of Managing Member at Matrix Capital Management Fund LP which he founded. Mr. Goel is on the board of The Museum of Fine Arts and 6 other companies. In the past Mr. Goel was Financial Analyst for Morgan Stanley, Associate Director at Tiger Management LLC and Associate of General Atlantic LLC. He received an undergraduate degree from Harvard University and an undergraduate degree from Phillips Exeter Academy.
Chad M. Cohen Currently, Chad M. Cohen occupies the position of CFO, Principal Financial & Accounting Officer at Adaptive Biotechnologies Corp. He is also on the board of Porch.com, Inc. In the past Mr. Cohen held the position of Chief Financial Officer & Treasurer at Zillow Group, Inc. and Chief Financial Officer & Treasurer for Zillow, Inc. (a subsidiary of Zillow Group, Inc.), Supervising Senior Auditor at Ernst & Young LLP, Manager-Financial & Assistant Controller at Ticketmaster Entertainment LLC, Financial Planning Analyst at Novellus Systems, Inc., Vice President & Assistant Controller at Countrywide Financial Corp. and Vice President & Assistant Controller at Countrywide Bank, FSB. Chad M. Cohen received an undergraduate degree from Boston University.
Chad Robins Founder of Adaptive Biotechnologies Corp. and Aortica Corp., Chad Robins currently holds the position of Chairman & Chief Executive Officer for Adaptive Biotechnologies Corp. He is also on the board of Aortica Corp. and Pavia Systems, Inc.
Michelle Griffin Michelle Griffin is on the board of HTG Molecular Diagnostics, Inc., Adaptive Biotechnologies Corp. and Acer Therapeutics, Inc. In the past she held the position of Principal at Pacific Biotechnology Consulting Group, Chairman for Universal Cells, Inc., Chief Operating Officer for Emergent Product Development Seattle, Chief Financial Officer & Senior Vice President at Dendreon Corp., Chief Financial Officer of OncoGenex Pharmaceuticals, Inc. and Chief Financial Officer of Corixa Corp. Michelle Griffin received an MBA from Seattle University and an undergraduate degree from George Mason University.
Harlan Robins Harlan Robins founded Adaptive Biotechnologies Corp. Presently, he is Chief Scientific Officer at this company.
Julie Rubinstein Julie Rubinstein holds the position of President at Adaptive Biotechnologies Corp. Ms. Rubinstein is also on the board of The Valerie Fund.
Francis Lo Currently, Francis Lo is Chief People Officer of Adaptive Biotechnologies Corp.
Charles Sang Charles Sang is Senior Vice President-Clinical Diagnostics at Adaptive Biotechnologies Corp.
Sharon Benzeno Sharon Benzeno is Senior Vice President-Drug Discovery at Adaptive Biotechnologies Corp.
Stacy Taylor Presently, Stacy Taylor occupies the position of General Counsel at Adaptive Biotechnologies Corp.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐